Biopharmaceutical company PolyPid Ltd said on Tuesday that it has received US Food and Drug Administration (FDA) second Qualified Infectious Disease Product (QIDP) designation for its lead drug product candidate D-PLEX100 for the prevention of post-abdominal surgery incisional infection.
Previously, the company's D-PLEX100 had received both QIDP designation and Fast Track status from the US FDA for the prevention of sternal wound infection post cardiac surgery, one of the most devastating complications with a mortality rate of up to 40% when deep sternal infection occurs.
Following the US FDA QIDP, the company now plans to start its Phase 3 clinical trial in cardiac surgery in the second half of 2019,with more than 140 patients already enrolled and with the top-line results expected in the second half of 2019
Upon administration of D-PLEX100 into the surgical site, the PLEX technology enables the prolonged and constant release of high local concentration of broad-spectrum antibiotic for a period of four weeks, allowing effective prevention of infection after surgery with increased potential to eradicate antibiotic resistant bacteria.
Additionally, the company's technology and products are based on the inventions of its founder and chief scientific officer Dr Noam Emanuel. Its PLEX-based products have demonstrated an excellent efficacy and safety profile during extended clinical trials, with more than 100 patients treated in clinical trials to date.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML